Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Parallel Group, Double-blind, Multi-center, Phase II Study to Assess the Clinical- and Immunological Activity,as Well as the Safety and Tolerability of Different Doses/Formulations of AFFITOPE AD02 Administered Repeatedly to Patients With Early Alzheimer's Disease

NCT01117818 is registered in ClinicalTrials.gov with Affiris AG as lead sponsor.

NCT NCT01117818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01117818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Parallel Group, Double-blind, Multi-center, Phase II Study to Assess the Clinical- and Immunological Activity,as Well as the Safety and Tolerability of Different Doses/Formulations of AFFITOPE AD02 Administered Repeatedly to Patients With Early Alzheimer's Disease
Lead sponsor
Affiris AG
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
December 31, 2013
Enrollment
335 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease